Revolution Medicines, Inc. (RVMD) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Redwood City, CA, アメリカ. 現CEOは Mark A. Goldsmith.
RVMD を有する IPO日 2020-02-13, 616 名の正社員, に上場 NASDAQ Global Select, 時価総額 $29.13B.
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel therapies targeting RAS-addicted cancers. The company's pipeline includes several investigational programs, such as RMC-4630, an SHP2 inhibitor currently in Phase 1/2 trials for solid tumors including gynecologic and colorectal cancers, as well as RMC-5845, RMC-5552, RMC-6291, and RMC-6236, which target various components of RAS signaling pathways. Revolution Medicines has established a collaboration with Sanofi for the research and development of SHP2 inhibitors. Founded in 2014 and based in Redwood City, California, the company is advancing precision medicine approaches to address cancers driven by RAS mutations.
